EquasensFRA:PHF 98 ROE % is 17.46% as of Dec. 2025, which is 24% below its 10-year median of 22.85. GuruFocus rates FRA:PHF with a GF Score™ of 98/100 and a GF Value™ of €85.09. The stock has 2 warning signs investors should review. Among 628 Healthcare Providers & Services companies, Equasens ranks better than 78.34% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Equasens's annualized net income for the quarter that ended in Dec. 2025 was €44.1 Mil. Equasens's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was €252.3 Mil. Therefore, Equasens's annualized ROE % for the quarter that ended in Dec. 2025 was 17.46%.
The historical rank and industry rank for Equasens's ROE % or its related term are showing as below:
FRA:PHF'
s ROE % Range Over the Past 10 Years
Min: 16.07 Med: 22.85 Max: 26.59
Current: 16.26
During the past 13 years, Equasens's highest ROE % was 26.59%. The lowest was 16.07%. And the median was 22.85%.
FRA:PHF's ROE % is ranked better than 78.34% of 628
companies
in the Healthcare Providers & Services industry
Industry Median: 5.72
vs FRA:PHF: 16.26
Equasens (FRA:PHF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Equasens ROE % Related Terms
Equasens ROE % Historical Data
* Premium members only.
The historical data trend for Equasens's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Equasens's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Equasens ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Equasens's ROE % distribution charts can be found below:
* The bar in red indicates where Equasens's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Equasens (FRA:PHF) has a ROE % of 17.46% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Equasens and its competitors. This is 24% below median its historical median of 22.85. Over the past decade, Equasens' ROE % has ranged from 16.07 to 26.59. According to the industry distribution chart, Equasens ranks #136 out of 628 companies in the Healthcare Providers & Services industry, placing it in the top 21.7%.
Is Equasens' ROE % too high?
Equasens' current ROE % of 17.46% is 24% below median its 10-year median of 22.85. Over the past 10 years, this metric has ranged from a low of 16.07 to a high of 26.59. The Healthcare Providers & Services industry median ROE % is 5.72. Equasens' value of 17.46% is 205.2% above this industry median. Based on the distribution chart, Equasens ranks #136 out of 628 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Equasens has a GF Score™ of 98/100, reflecting its overall financial health beyond just this single metric.
How does Equasens' ROE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Equasens ranks #136 out of 628 companies for ROE %. This places Equasens in the top 22% of its industry — outperforming the majority of peers. The industry median ROE % is 5.72. Equasens' value of 17.46% is 205.2% above this benchmark. Historically, Equasens' own ROE % has ranged from 16.07 to 26.59 over the past decade. While the company's 10-year median is 22.85 vs. the industry median of 5.72, Equasens has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.72, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Equasens's current ROE % of 17.46% is 205.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Equasens and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Equasens's current ROE % is 17.46%, which is 24% below median its own 10-year median of 22.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equasens stock overvalued right now?
Equasens (FRA:PHF) has a current ROE % of 17.46%. The stock's GF Value™ is €85.09, compared to a current price of €52.77 — trading 38% below its estimated fair value. The current ROE % is 17.46%, which is 24% below median its 10-year median of 22.85 and 205.2% above the Healthcare Providers & Services industry median of 5.72. Equasens' overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Equasens (FRA:PHF), the current ROE % is 17.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Equasens (FRA:PHF) Overvalued in 2026?
Based on GuruFocus' analysis, Equasens stock appears to be undervalued.
The current stock price of €52.77 is trading 38% below its estimated GF Value™ of €85.09.
Key valuation signals for FRA:PHF:
ROE %: 17.46% (24% below median its 10-year median of 22.85)
GF Value™: €85.09 vs. price of €52.77 (38% below fair value)
Industry Position: 205.2% above the Healthcare Providers & Services median (#136 of 628)
No single metric tells the full story. See the FRA:PHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
98GF Score
Get the complete analysis for FRA:PHF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHF has been successfully added to your 
